Arthritis & Rheumatism

FDA expands pediatric indication for Rinvoq

The U.S. Food and Drug Administration has expanded indications for AbbVie's Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic ...

Oncology & Cancer

FDA approves augtyro for NTRK-positive advanced solid tumors

The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with neurotrophic tyrosine receptor kinase (NTRK)-positive locally ...

page 2 from 40